4D Molecular (FDMT) Therapeutics announced senior leadership additions and changes that align with the Company’s focus on late-stage clinical trial and BLA execution and commercial readiness. Julie Clark, M.D., was promoted to Chief Medical Officer, CMO. Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality. Robert Kim, M.D., has stepped down from his role as Chief Medical Officer to pursue other opportunities, effective August 30, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- Buy Rating Affirmed for 4D-150: Promising Phase 2a SPECTRA Trial Results and Market Potential
- 4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement Landscape
- 4D Molecular Therapeutics Advances Clinical Programs in Q2 2025
- 4D Molecular price target lowered to $16 from $17 at Leerink
- Morning Movers: MeridianLink jumps after pact to be acquired by Centerbridge